Is recombinant human TSH as effective as thyroid hormone withdrawal in the detection and treatment of metastatic differentiated thyroid cancer?
Evaluation of: Van Nostr D, Khorjekav GR, O'Neil J et al. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole body imaging and 124I PET. J. Nucl. Med 53(3), 359-362 (2012). In a recent article, Van Nostrand et al. compared two methods of patient preparation, that is, recombinant human thyroid-stimulating hormone and thyroid hormone withdrawal, for the detection of metastasis in patients previously treated for differentiated thyroid cancer, using both 131I whole-body imaging and 124I positron emission tomography. The major finding of this prospective study was that the number of patients and the number of foci for patient positive at 131I whole-body imaging and 124I PET performed after thyroid hormone withdrawal was significantly higher when compared with that related to patients prepared with recombinant human thyroid-stimulating hormone.